767.33
前日終値:
$737.56
開ける:
$775.92
24時間の取引高:
508.34K
Relative Volume:
1.25
時価総額:
$46.96B
収益:
$3.06B
当期純損益:
$1.28B
株価収益率:
39.01
EPS:
19.6719
ネットキャッシュフロー:
$447.35M
1週間 パフォーマンス:
+5.15%
1か月 パフォーマンス:
+7.74%
6か月 パフォーマンス:
+35.31%
1年 パフォーマンス:
+40.21%
Argen X Se Adr Stock (ARGX) Company Profile
ARGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ARGX
Argen X Se Adr
|
767.33 | 45.14B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
404.21 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
599.94 | 59.59B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.65 | 59.77B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
ONC
Beone Medicines Ltd Adr
|
335.16 | 37.42B | 4.56B | -176.77M | 225.30M | -1.7177 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-09-15 | 再開されました | Truist | Buy |
2025-09-11 | ダウングレード | Deutsche Bank | Buy → Hold |
2025-08-25 | 開始されました | RBC Capital Mkts | Outperform |
2025-07-08 | アップグレード | Deutsche Bank | Hold → Buy |
2025-07-03 | 再開されました | Morgan Stanley | Overweight |
2025-05-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
2024-10-10 | 再開されました | Raymond James | Strong Buy |
2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-07-31 | 開始されました | Scotiabank | Sector Perform |
2023-07-24 | ダウングレード | UBS | Buy → Neutral |
2023-07-17 | 再開されました | Evercore ISI | Outperform |
2023-06-15 | 開始されました | Societe Generale | Sell |
2023-05-31 | 開始されました | UBS | Buy |
2023-04-25 | 開始されました | Citigroup | Buy |
2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
2022-12-07 | 開始されました | William Blair | Outperform |
2022-10-12 | 開始されました | Oppenheimer | Perform |
2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2022-06-28 | 再開されました | Stifel | Buy |
2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-12-08 | 開始されました | Wells Fargo | Overweight |
2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-09-23 | アップグレード | Redburn | Neutral → Buy |
2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-07-23 | 開始されました | Deutsche Bank | Hold |
2021-07-19 | 再開されました | Wolfe Research | Outperform |
2021-06-18 | 開始されました | UBS | Buy |
2021-06-04 | 再開されました | Robert W. Baird | Outperform |
2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
2021-04-23 | 開始されました | Redburn | Neutral |
2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
2020-08-25 | 開始されました | Raymond James | Outperform |
2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
2020-02-10 | 開始されました | BofA/Merrill | Buy |
2019-11-05 | 開始されました | Credit Suisse | Neutral |
2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
2019-10-22 | 開始されました | JP Morgan | Overweight |
2019-09-27 | 開始されました | Wells Fargo | Market Perform |
2019-09-16 | 再開されました | Cowen | Outperform |
2019-06-28 | 開始されました | Robert W. Baird | Outperform |
2019-01-18 | 再開されました | SunTrust | Buy |
2019-01-04 | 開始されました | Morgan Stanley | Overweight |
2018-12-17 | 開始されました | Goldman | Buy |
2018-12-14 | 開始されました | Wolfe Research | Outperform |
2018-06-29 | 開始されました | Nomura | Buy |
2018-04-09 | 開始されました | SunTrust | Buy |
2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
Argenx stock hits all-time high at 781.12 USD - Investing.com
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm
Argenx Se (ARGX) Receives a Rating Update from a Top Analyst - The Globe and Mail
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
14 Newly Overvalued Stocks for the Week - Morningstar
Argenx stock hits all-time high at 716.89 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily
Argenx stock reaches all-time high at 696.94 USD - Investing.com
Argenx: study met primary endpoint - AInvest
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewswire Inc.
Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com
Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.
This Stock Ran 31% In A Month. Will Upcoming News Revitalize It? - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl
Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa
Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria
argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com South Africa
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
Argenx stock price target reiterated at $761 on positive trial data - Investing.com
argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com
argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily
10 Stocks Analysts Are Upgrading Today - Insider Monkey
JMP cuts argenx stock target to $699, keeps outperform rating - Investing.com
Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar
Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily
argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade - inkl
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa
Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily
Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India
Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India
Stifel maintains $780 target on argenx stock after FDA nod - Investing.com
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):